Well I'm typically conservative in my estimates. My expectation was just $60m, so it was better than I thought, or maybe on target if you take out BARDA reimbursement.
But I try to think where extra growth is coming from next year. 45% in USA, but we see the growth from ROW is making significant gains and I think that's the important feature. The increase in sales people in the USA and the increase in price together with higher revenues from individual accounts will drive US growth. UK-Europe-Canada-India-Australia-NZ will all contribute a bit, along with BARDA.
So $65m from US, $20m-$25m RoW and $5m BARDA =$90m? 40+% growth FY2024
That's good enough for me, with potentially BARDA and DFU ulcer trial results in 2025, greater reinbursement, greater contributions from new markets like India and many more publications to take revenues to $135m in 2025.
PNV Price at posting:
$1.52 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)